Please assess the completion status of the following clinical trial:

Trial Title: A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy volunteers.~2. Age: 19-45, males and females.~3. The weight is within ± 10% of the standard weight \[standard weight (kg) = 0.7 × (height cm-80)\].~4. Examination indices of heart, liver, kidney and blood are all within the normal range.~5. According to Good Clinical Practice (GCP), volunteers who understand and voluntarily sign the consent form before this study.~Exclusion Criteria:~1. Women in pregnancy or lactation.~2. Primary diseases of important organs.~3. Mentally or physically disabled patients.~4. Suspected or definite history of alcohol and drug abuse.~5. According to the investigator's judgment, there is a low possibility of enrollment (such as frailty, etc.).~6. Volunteers who are allergic to the components of this medicine, or have a history of allergies to two or more drugs or food.~7. Volunteers who have diseases (such as insomnia) and are using other preventive and therapeutic drugs before this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
- 2X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
- 4X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
- 6X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
- 8X level (Type: EXPERIMENTAL): Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).